Targets

Target Filters...

This is where graphics are reside..

Name	Gene	Development Level	Target Family	Log Novelty	Pubmed Score	Antibody Count
Metal-response element-binding transcription factor 2	MTF2	Tbio	Epigenetic	-1.74028	52.0	101
Zinc finger protein 334	ZNF334	Tdark	Transcription Factor	-0.12494	1.43	22
Lebercilin	LCA5	Tbio	Non-IDG	-1.21162	16.7	65
Solute carrier organic anion transporter family member 3A1	SLCO3A1	Tbio	Transporter	-1.38328	23.0	28
5'-AMP-activated protein kinase subunit beta-1	PRKAB1	Tbio	Kinase	-1.47950	28.8	495
AP-5 complex subunit sigma-1	AP5S1	Tdark	Non-IDG		0.00000	2
Palmitoyltransferase ZDHHC2	ZDHHC2	Tbio	Enzyme	-1.85412	69.1	64
E3 ISG15--protein ligase HERC5	HERC5	Tbio	Enzyme	-1.59626	41.3	53
Rho GDP-dissociation inhibitor 3	ARHGDIG	Tbio	Non-IDG	-0.79022	8.54	95
Soluble calcium-activated nucleotidase 1	CANT1	Tbio	Enzyme	-1.42022	25.3	175

	Tbio	1,218 \| 10,625
	Tdark	391 \| 7,003
	Tchem	202 \| 1,890
	Tclin	64 \| 602

	Eligible Kinase Proteins	20 \| 134
	Eligible Ion Channel Proteins	11 \| 117
	Eligible non-olfactory GPCR Proteins	6 \| 145

	preweaning lethality, complete...	69 \| 633
	preweaning lethality, incomple...	45 \| 260
	decreased total body fat amoun...	34 \| 186
	abnormal behavior	31 \| 226
	decreased lean body mass	27 \| 195
	decreased bone mineral content	21 \| 157
	decreased body weight	20 \| 174
	abnormal bone structure	19 \| 131
	decreased bone mineral density	17 \| 126
	decreased grip strength	17 \| 123
	decreased body length	16 \| 108
	embryonic lethality prior to t...	16 \| 187
	hyperactivity	16 \| 108
	increased lean body mass	16 \| 107
	increased or absent threshold ...	16 \| 128
	increased bone mineral content	15 \| 92
	abnormal embryo size	13 \| 112
	abnormal retina morphology	13 \| 100
	decreased circulating HDL chol...	13 \| 77
	decreased circulating choleste...	12 \| 85
	increased circulating alkaline...	12 \| 119
	abnormal gait	11 \| 51
	abnormal lens morphology	11 \| 73
	increased circulating sodium l...	11 \| 71
	increased mean corpuscular vol...	11 \| 91
	decreased circulating glucose ...	10 \| 121
	decreased rib number	10 \| 59
	increased bone mineral density	10 \| 52
	increased total body fat amoun...	10 \| 57
	short tibia	10 \| 82
	abnormal sleep behavior	9 \| 63
	enlarged heart	9 \| 111
	hypoactivity	9 \| 89
	impaired glucose tolerance	9 \| 52
	increased blood urea nitrogen ...	9 \| 44
	increased circulating choleste...	9 \| 53
	increased mean corpuscular hem...	9 \| 93
	abnormal heart morphology	8 \| 51
	abnormal retinal blood vessel ...	8 \| 18
	abnormal retinal pigmentation	8 \| 61
	decreased blood urea nitrogen ...	8 \| 31
	decreased circulating serum al...	8 \| 79
	decreased circulating triglyce...	8 \| 83
	decreased erythrocyte cell num...	8 \| 43
	increased circulating HDL chol...	8 \| 63
	male infertility	8 \| 62
	prenatal lethality prior to he...	8 \| 64
	small testis	8 \| 37
	abnormal bone mineralization	7 \| 55
	abnormal seminal vesicle morph...	7 \| 47
	abnormal testis morphology	7 \| 30
	abnormal tooth morphology	7 \| 24
	decreased fasted circulating g...	7 \| 49
	decreased hemoglobin content	7 \| 53
	decreased mean corpuscular vol...	7 \| 50
	increased circulating calcium ...	7 \| 32
	abnormal coat appearance	6 \| 25
	abnormal coat/hair pigmentatio...	6 \| 54
	abnormal retinal vasculature m...	6 \| 15
	decreased circulating LDL chol...	6 \| 37
	decreased circulating creatini...	6 \| 31
	decreased hematocrit	6 \| 25
	decreased leukocyte cell numbe...	6 \| 54
	decreased mean corpuscular hem...	6 \| 19
	decreased monocyte cell number	6 \| 28
	decreased startle reflex	6 \| 48
	enlarged lymph nodes	6 \| 27
	immune system phenotype	6 \| 17
	increased body weight	6 \| 42
	increased circulating triglyce...	6 \| 24
	increased exploration in new e...	6 \| 56
	increased grip strength	6 \| 83
	increased hematocrit	6 \| 36
	increased hemoglobin content	6 \| 45
	increased red blood cell distr...	6 \| 21
	thrombocytopenia	6 \| 46
	abnormal cornea morphology	5 \| 24
	abnormal cranium morphology	5 \| 32
	abnormal neural tube closure	5 \| 37
	abnormal skin morphology	5 \| 23
	corneal opacity	5 \| 25
	decreased circulating free fat...	5 \| 39
	decreased eosinophil cell numb...	5 \| 41
	decreased lumbar vertebrae num...	5 \| 62
	decreased mean corpuscular hem...	5 \| 34
	embryonic lethality prior to o...	5 \| 148
	improved glucose tolerance	5 \| 56
	increased circulating chloride...	5 \| 43
	increased circulating phosphat...	5 \| 24
	increased fasted circulating g...	5 \| 68
	increased mean platelet volume	5 \| 19
	increased neutrophil cell numb...	5 \| 15
	increased rib number	5 \| 41
	limb grasping	5 \| 35
	straub tail	5 \| 26
	abnormal epididymis morphology	4 \| 31
	decreased circulating fructosa...	4 \| 31
	decreased circulating insulin ...	4 \| 75
	decreased prepulse inhibition	4 \| 52
	increased prepulse inhibition	4 \| 21

	group 4 medulloblastoma	1,875 \| 1,875
	ovarian cancer	8,492 \| 8,492
	osteosarcoma	7,933 \| 7,933
	psoriasis	6,685 \| 6,685
	medulloblastoma, large-cell	6,234 \| 6,234
	glioblastoma	5,572 \| 5,572
	lung cancer	4,473 \| 4,473
	atypical teratoid / rhabdoid tumor	4,369 \| 4,369
	intraductal papillary-mucinous neoplasm (IPMN)	3,289 \| 3,289
	malignant mesothelioma	3,163 \| 3,163
	Breast cancer	3,099 \| 3,099
	pilocytic astrocytoma	3,086 \| 3,086
	primitive neuroectodermal tumor	3,031 \| 3,031
	intraductal papillary-mucinous carcinoma (IPMC)	2,988 \| 2,988
	intraductal papillary-mucinous adenoma (IPMA)	2,956 \| 2,956
	invasive ductal carcinoma	2,950 \| 2,950
	oligodendroglioma	2,849 \| 2,849
	lung carcinoma	2,844 \| 2,844
	non-small cell lung cancer	2,798 \| 2,798
	lung adenocarcinoma	2,714 \| 2,714
	pediatric high grade glioma	2,712 \| 2,712
	ependymoma	2,514 \| 2,514
	Cancer	2,346 \| 2,346
	pancreatic cancer	2,300 \| 2,300
	interstitial cystitis	2,299 \| 2,299
	subependymal giant cell astrocytoma	2,287 \| 2,287
	group 3 medulloblastoma	2,254 \| 2,254
	astrocytic glioma	2,241 \| 2,241
	adult high grade glioma	2,148 \| 2,148
	Carcinoma	2,147 \| 2,147
	ulcerative colitis	2,087 \| 2,087
	pituitary cancer	1,972 \| 1,972
	Pick disease	1,893 \| 1,893
	pancreatic ductal adenocarcinoma liver metastasis	1,795 \| 1,795
	ductal carcinoma in situ	1,745 \| 1,745
	cystic fibrosis	1,670 \| 1,670
	diabetes mellitus	1,663 \| 1,663
	breast carcinoma	1,614 \| 1,614
	tuberculosis	1,563 \| 1,563
	posterior fossa group B ependymoma	1,530 \| 1,530
	medulloblastoma	1,524 \| 1,524
	posterior fossa group A ependymoma	1,511 \| 1,511
	astrocytoma	1,493 \| 1,493
	sonic hedgehog group medulloblastoma	1,482 \| 1,482
	colon cancer	1,475 \| 1,475
	adrenocortical carcinoma	1,427 \| 1,427
	Multiple myeloma	1,328 \| 1,328
	primary pancreatic ductal adenocarcinoma	1,271 \| 1,271
	juvenile dermatomyositis	1,189 \| 1,189
	Rheumatoid Arthritis	1,171 \| 1,171
	acute quadriplegic myopathy	1,157 \| 1,157
	atypical teratoid/rhabdoid tumor	1,095 \| 1,095
	spina bifida	1,064 \| 1,064
	cutaneous lupus erythematosus	1,056 \| 1,056
	nasopharyngeal carcinoma	1,056 \| 1,056
	dermatomyositis	967 \| 967
	Atopic dermatitis	944 \| 944
	active Crohn's disease	918 \| 918
	non primary Sjogren syndrome sicca	840 \| 840
	gastric carcinoma	832 \| 832
	primary Sjogren syndrome	789 \| 789
	acute myeloid leukemia	785 \| 785
	Waldenstrons macroglobulinemia	765 \| 765
	esophageal adenocarcinoma	737 \| 737
	tuberculosis and treatment for 6 months	686 \| 686
	progressive supranuclear palsy	674 \| 674
	aldosterone-producing adenoma	664 \| 664
	Alzheimer's disease	644 \| 644
	Obesity	616 \| 616
	Duchenne muscular dystrophy	602 \| 602
	Intellectual disability	573 \| 573
	pancreatic carcinoma	567 \| 567
	fibroadenoma	557 \| 557
	hepatocellular carcinoma	550 \| 550
	Down syndrome	548 \| 548
	Endometriosis	535 \| 535
	chronic rhinosinusitis	512 \| 512
	Schizophrenia	503 \| 503
	autosomal dominant Emery-Dreifuss muscular dystrophy	499 \| 499
	Multiple Sclerosis	498 \| 498
	mucosa-associated lymphoid tissue lymphoma	480 \| 480
	active ulcerative colitis	477 \| 477
	Prostatic Neoplasms	471 \| 471
	IGA Glomerulonephritis	454 \| 454
	gastric cancer	436 \| 436
	Amyotrophic Lateral Sclerosis	432 \| 432
	non-small cell lung carcinoma	413 \| 413
	Mammary Neoplasms	410 \| 410
	inflammatory breast cancer	404 \| 404
	Kidney disease	397 \| 397
	Neurodegenerative disease	383 \| 383
	sarcoidosis	368 \| 368
	Parkinson's disease	364 \| 364
	Asthma	349 \| 349
	glioblastoma multiforme	347 \| 347
	Epilepsy	346 \| 346
	Polycystic Ovary Syndrome	335 \| 335
	nephrosclerosis	329 \| 329
	tuberculosis and treatment for 3 months	327 \| 327
	Autistic Disorder	320 \| 320

	Female tissues	1,859 \| 18,647
	Digestive Tract	1,858 \| 18,473
	Nervous System	1,856 \| 18,561
	Blood and immune system	1,853 \| 17,995
	Liver and Pancreas	1,853 \| 18,136
	Urinary Tract	1,853 \| 18,444
	Male tissues	1,852 \| 17,969
	Endocrine System	1,851 \| 18,512
	Cardiovascular System	1,849 \| 17,958
	Skin and soft tissues	1,836 \| 18,115
	Respiratory system	1,832 \| 17,484

Development Level

Collection

IMPC Term

Disease

Tissue

Target Family

Drug Target Ontology

Target Development Level

Target Family

PANTHER Protein Ontology

Ligand

GTEx Tissue

HPA RNA Tissue

HPA Protein Tissue

HPM Tissue

JAX/MGI Phenotype

OMIM Phenotype

GWAS Trait

GO Component

UniProt Keywords

Grant Funding IC

Grant Activity

Data Source

	Non-IDG	1,006 \| 11,969
	Enzyme	418 \| 4,146
	Transcription Factor	228 \| 1,400
	Kinase	77 \| 634
	Transporter	47 \| 473
	Ion Channel	33 \| 341
	GPCR	26 \| 408
	Epigenetic	23 \| 242
	Nuclear Receptor	13 \| 48
	TF/Epigenetic	3 \| 38
	oGPCR	1 \| 421